Keytruda (pembrolizumab) is given as an intravenous (IV) infusion that takes 30 minutes. The drug is delivered directly into a vein through an IV line, typically at a hospital or clinic infusion center. There is no pill or injection form.
What Happens During an Infusion
Before the drug reaches your vein, pharmacy staff dilute it into an IV bag containing either saline or a dextrose solution. The IV line uses a special filter to catch any microscopic particles before they enter your bloodstream. Once everything is set up, the infusion itself runs for 30 minutes.
Your care team will check your vital signs before starting and monitor you throughout the infusion. You’ll be seated in a chair, and many patients read, watch something on their phone, or simply rest during the half hour. There’s no required fasting, special hydration, or routine premedication beforehand, which makes it simpler than many other cancer treatments. That said, your oncologist may occasionally recommend an antihistamine or fever reducer if you’ve had a reaction in the past.
Plan for your visit to take longer than 30 minutes. Check-in, vitals, IV placement, and a short observation period afterward all add time. Most people spend one to two hours at the infusion center for each session.
Dosing Schedules
For adults, Keytruda is given on one of two schedules:
- 200 mg every 3 weeks
- 400 mg every 6 weeks
Both options are FDA-approved across nearly all of Keytruda’s cancer indications, whether it’s used alone or combined with other treatments. The 6-week schedule delivers a larger dose less frequently, which means fewer trips to the infusion center. Your oncologist will choose the schedule that fits your treatment plan and lifestyle. In either case, the infusion still takes 30 minutes per session.
For some cancers, treatment continues for up to 24 months as long as the disease isn’t progressing and side effects remain manageable. For others, particularly when Keytruda is used after surgery to reduce the risk of recurrence, the duration may be shorter and defined by the specific treatment protocol.
Where Infusions Take Place
Most people receive Keytruda at a hospital-based or outpatient chemotherapy day unit. These are same-day visits with no overnight stay required. Some cancer centers have dedicated infusion suites with individual bays or private rooms.
Home infusion is an emerging option for certain low-risk IV cancer therapies. Some immunotherapy regimens that don’t carry a high risk of severe reactions can be safely given at home after the first dose is completed in a clinical setting. However, home delivery of Keytruda is not yet standard practice, and most oncologists still prefer the infusion center where monitoring equipment and trained staff are immediately available.
Infusion Reactions
About 3% of patients experience some type of infusion-related reaction during or shortly after a Keytruda session. The most common symptoms are fever and chills. These are typically mild.
Severe or life-threatening reactions, such as significant allergic responses, occur in roughly 0.2% of patients. If a mild reaction happens, the nursing team will slow or temporarily pause the infusion and treat your symptoms. For serious reactions, the infusion is stopped and Keytruda is permanently discontinued. This is rare, but it’s one reason infusion centers keep emergency supplies on hand and monitor patients closely.
Your team will likely ask you to stay for a brief observation window after your first few infusions. If you’ve tolerated several sessions without issues, that monitoring period may be shortened over time.
How Keytruda Differs From Chemotherapy Infusions
If you’ve experienced traditional chemotherapy, Keytruda’s infusion process is noticeably shorter. Many chemo regimens take several hours per session and require pre-treatment with anti-nausea drugs, steroids, or fluids. Keytruda’s 30-minute infusion with no mandatory premedication is considerably less involved. The side effect profile is also different: because Keytruda works by helping your immune system recognize cancer cells rather than by killing fast-dividing cells, the typical chemotherapy side effects like hair loss and severe nausea are not characteristic of Keytruda treatment. Immune-related side effects can still occur between infusions, but the infusion day itself tends to be straightforward for most patients.